Compile Data Set for Download or QSAR
Report error Found 108 Enz. Inhib. hit(s) with all data for entry = 10064
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM511610(US11059801, Compound dBET18)
Affinity DataIC50: 1.57nMAssay Description:A thalidomide competition AlphaScreen assay was employed to measure the binding affinity (IC50) of thalidomide conjugates and novel IMiDs to CRBN-DDB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50544938(CHEMBL4094346 | US11059801, Compound dBET1)
Affinity DataIC50: 3.09nMAssay Description:A thalidomide competition AlphaScreen assay was employed to measure the binding affinity (IC50) of thalidomide conjugates and novel IMiDs to CRBN-DDB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM511611(US11059801, Compound dBET19)
Affinity DataIC50: 3.62nMAssay Description:A thalidomide competition AlphaScreen assay was employed to measure the binding affinity (IC50) of thalidomide conjugates and novel IMiDs to CRBN-DDB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM511608(US11059801, Compound dBET16)
Affinity DataIC50: 4.84nMAssay Description:A thalidomide competition AlphaScreen assay was employed to measure the binding affinity (IC50) of thalidomide conjugates and novel IMiDs to CRBN-DDB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM511621(US11059801, Compound dBET29)
Affinity DataIC50: 6.05nMAssay Description:A thalidomide competition AlphaScreen assay was employed to measure the binding affinity (IC50) of thalidomide conjugates and novel IMiDs to CRBN-DDB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM511609(US11059801, Compound dBET17)
Affinity DataIC50: 6.41nMAssay Description:A thalidomide competition AlphaScreen assay was employed to measure the binding affinity (IC50) of thalidomide conjugates and novel IMiDs to CRBN-DDB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

LigandPNGBDBM511627(US11059801, Compound dBET35)
Affinity DataIC50: 7.21nMAssay Description:AlphaScreen technology was used to detect CRBN-DDB1/BRD4 dimerization induced by dBET molecules. In brief, GST-BRD4[49-170] (Sigma Aldrich) and CRBN-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM511594(US11059801, Compound dBET2)
Affinity DataIC50: 7.30nMAssay Description:A thalidomide competition AlphaScreen assay was employed to measure the binding affinity (IC50) of thalidomide conjugates and novel IMiDs to CRBN-DDB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM511616(US11059801, Compound dBET24)
Affinity DataIC50: 10.3nMAssay Description:A thalidomide competition AlphaScreen assay was employed to measure the binding affinity (IC50) of thalidomide conjugates and novel IMiDs to CRBN-DDB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM511595(US11059801, Compound dBET3)
Affinity DataIC50: 10.4nMAssay Description:A thalidomide competition AlphaScreen assay was employed to measure the binding affinity (IC50) of thalidomide conjugates and novel IMiDs to CRBN-DDB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM511605(US11059801, Compound dBET13)
Affinity DataIC50: 10.7nMAssay Description:A thalidomide competition AlphaScreen assay was employed to measure the binding affinity (IC50) of thalidomide conjugates and novel IMiDs to CRBN-DDB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

LigandPNGBDBM511610(US11059801, Compound dBET18)
Affinity DataIC50: 11nMAssay Description:AlphaScreen technology was used to detect CRBN-DDB1/BRD4 dimerization induced by dBET molecules. In brief, GST-BRD4[49-170] (Sigma Aldrich) and CRBN-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM511664(US11059801, Compound D-31)
Affinity DataIC50: 12.1nMAssay Description:A thalidomide competition AlphaScreen assay was employed to measure the binding affinity (IC50) of thalidomide conjugates and novel IMiDs to CRBN-DDB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM511606(US11059801, Compound dBET14)
Affinity DataIC50: 12.4nMAssay Description:A thalidomide competition AlphaScreen assay was employed to measure the binding affinity (IC50) of thalidomide conjugates and novel IMiDs to CRBN-DDB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM511602(US11059801, Compound dBET10)
Affinity DataIC50: 12.7nMAssay Description:A thalidomide competition AlphaScreen assay was employed to measure the binding affinity (IC50) of thalidomide conjugates and novel IMiDs to CRBN-DDB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

LigandPNGBDBM511629(US11059801, Compound dBET37)
Affinity DataIC50: 13.2nMAssay Description:AlphaScreen technology was used to detect CRBN-DDB1/BRD4 dimerization induced by dBET molecules. In brief, GST-BRD4[49-170] (Sigma Aldrich) and CRBN-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

LigandPNGBDBM511598(US11059801, Compound dBET6)
Affinity DataIC50: 14nMAssay Description:AlphaScreen technology was used to detect CRBN-DDB1/BRD4 dimerization induced by dBET molecules. In brief, GST-BRD4[49-170] (Sigma Aldrich) and CRBN-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM511601(US11059801, Compound dBET9)
Affinity DataIC50: 14.8nMAssay Description:A thalidomide competition AlphaScreen assay was employed to measure the binding affinity (IC50) of thalidomide conjugates and novel IMiDs to CRBN-DDB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

LigandPNGBDBM511601(US11059801, Compound dBET9)
Affinity DataIC50: 15nMAssay Description:AlphaScreen technology was used to detect CRBN-DDB1/BRD4 dimerization induced by dBET molecules. In brief, GST-BRD4[49-170] (Sigma Aldrich) and CRBN-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM511663(US11059801, Compound D-30)
Affinity DataIC50: 15.2nMAssay Description:A thalidomide competition AlphaScreen assay was employed to measure the binding affinity (IC50) of thalidomide conjugates and novel IMiDs to CRBN-DDB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM511620(US11059801, Compound dBET28)
Affinity DataIC50: 17.1nMAssay Description:A thalidomide competition AlphaScreen assay was employed to measure the binding affinity (IC50) of thalidomide conjugates and novel IMiDs to CRBN-DDB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

LigandPNGBDBM50544938(CHEMBL4094346 | US11059801, Compound dBET1)
Affinity DataIC50: 20nMAssay Description:AlphaScreen technology was used to detect CRBN-DDB1/BRD4 dimerization induced by dBET molecules. In brief, GST-BRD4[49-170] (Sigma Aldrich) and CRBN-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM511665(US11059801, Compound D-32)
Affinity DataIC50: 21.4nMAssay Description:A thalidomide competition AlphaScreen assay was employed to measure the binding affinity (IC50) of thalidomide conjugates and novel IMiDs to CRBN-DDB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM511604(US11059801, Compound dBET12)
Affinity DataIC50: 23.8nMAssay Description:A thalidomide competition AlphaScreen assay was employed to measure the binding affinity (IC50) of thalidomide conjugates and novel IMiDs to CRBN-DDB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

LigandPNGBDBM511634(US11059801, Compound dBET43)
Affinity DataIC50: 24.5nMAssay Description:AlphaScreen technology was used to detect CRBN-DDB1/BRD4 dimerization induced by dBET molecules. In brief, GST-BRD4[49-170] (Sigma Aldrich) and CRBN-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM511603(US11059801, Compound dBET11)
Affinity DataIC50: 25.1nMAssay Description:A thalidomide competition AlphaScreen assay was employed to measure the binding affinity (IC50) of thalidomide conjugates and novel IMiDs to CRBN-DDB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM511652(US11059801, Compound D-18)
Affinity DataIC50: 25.3nMAssay Description:A thalidomide competition AlphaScreen assay was employed to measure the binding affinity (IC50) of thalidomide conjugates and novel IMiDs to CRBN-DDB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM511622(US11059801, Compound dBET30)
Affinity DataIC50: 26.5nMAssay Description:A thalidomide competition AlphaScreen assay was employed to measure the binding affinity (IC50) of thalidomide conjugates and novel IMiDs to CRBN-DDB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM511623(US11059801, Compound dBET31)
Affinity DataIC50: 26.8nMAssay Description:A thalidomide competition AlphaScreen assay was employed to measure the binding affinity (IC50) of thalidomide conjugates and novel IMiDs to CRBN-DDB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM511615(US11059801, Compound dBET23)
Affinity DataIC50: 26.9nMAssay Description:A thalidomide competition AlphaScreen assay was employed to measure the binding affinity (IC50) of thalidomide conjugates and novel IMiDs to CRBN-DDB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

LigandPNGBDBM511633(US11059801, Compound dBET42)
Affinity DataIC50: 26.9nMAssay Description:AlphaScreen technology was used to detect CRBN-DDB1/BRD4 dimerization induced by dBET molecules. In brief, GST-BRD4[49-170] (Sigma Aldrich) and CRBN-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM511614(US11059801, Compound dBET22)
Affinity DataIC50: 28.4nMAssay Description:A thalidomide competition AlphaScreen assay was employed to measure the binding affinity (IC50) of thalidomide conjugates and novel IMiDs to CRBN-DDB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM511638(US11059801, Compound D-1 | US11059801, Compound D-...)
Affinity DataIC50: 28.9nMAssay Description:A thalidomide competition AlphaScreen assay was employed to measure the binding affinity (IC50) of thalidomide conjugates and novel IMiDs to CRBN-DDB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

LigandPNGBDBM511635(US11059801, Compound dBET44)
Affinity DataIC50: 30nMAssay Description:AlphaScreen technology was used to detect CRBN-DDB1/BRD4 dimerization induced by dBET molecules. In brief, GST-BRD4[49-170] (Sigma Aldrich) and CRBN-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

LigandPNGBDBM511607(US11059801, Compound dBET15)
Affinity DataIC50: 31nMAssay Description:AlphaScreen technology was used to detect CRBN-DDB1/BRD4 dimerization induced by dBET molecules. In brief, GST-BRD4[49-170] (Sigma Aldrich) and CRBN-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

LigandPNGBDBM511630(US11059801, Compound dBET38)
Affinity DataIC50: 31.4nMAssay Description:AlphaScreen technology was used to detect CRBN-DDB1/BRD4 dimerization induced by dBET molecules. In brief, GST-BRD4[49-170] (Sigma Aldrich) and CRBN-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

LigandPNGBDBM511595(US11059801, Compound dBET3)
Affinity DataIC50: 32nMAssay Description:AlphaScreen technology was used to detect CRBN-DDB1/BRD4 dimerization induced by dBET molecules. In brief, GST-BRD4[49-170] (Sigma Aldrich) and CRBN-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

LigandPNGBDBM511597(US11059801, Compound dBET5)
Affinity DataIC50: 33nMAssay Description:AlphaScreen technology was used to detect CRBN-DDB1/BRD4 dimerization induced by dBET molecules. In brief, GST-BRD4[49-170] (Sigma Aldrich) and CRBN-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM511600(US11059801, Compound dBET8)
Affinity DataIC50: 37.2nMAssay Description:A thalidomide competition AlphaScreen assay was employed to measure the binding affinity (IC50) of thalidomide conjugates and novel IMiDs to CRBN-DDB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM511613(US11059801, Compound dBET21)
Affinity DataIC50: 39nMAssay Description:A thalidomide competition AlphaScreen assay was employed to measure the binding affinity (IC50) of thalidomide conjugates and novel IMiDs to CRBN-DDB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM511661(US11059801, Compound D-28)
Affinity DataIC50: 40.1nMAssay Description:A thalidomide competition AlphaScreen assay was employed to measure the binding affinity (IC50) of thalidomide conjugates and novel IMiDs to CRBN-DDB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM511607(US11059801, Compound dBET15)
Affinity DataIC50: 40.4nMAssay Description:A thalidomide competition AlphaScreen assay was employed to measure the binding affinity (IC50) of thalidomide conjugates and novel IMiDs to CRBN-DDB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM511619(US11059801, Compound dBET27)
Affinity DataIC50: 41.1nMAssay Description:A thalidomide competition AlphaScreen assay was employed to measure the binding affinity (IC50) of thalidomide conjugates and novel IMiDs to CRBN-DDB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

LigandPNGBDBM511609(US11059801, Compound dBET17)
Affinity DataIC50: 46nMAssay Description:AlphaScreen technology was used to detect CRBN-DDB1/BRD4 dimerization induced by dBET molecules. In brief, GST-BRD4[49-170] (Sigma Aldrich) and CRBN-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM511658(US11059801, Compound D-25)
Affinity DataIC50: 58.9nMAssay Description:A thalidomide competition AlphaScreen assay was employed to measure the binding affinity (IC50) of thalidomide conjugates and novel IMiDs to CRBN-DDB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

LigandPNGBDBM511632(US11059801, Compound dBET41)
Affinity DataIC50: 62.8nMAssay Description:AlphaScreen technology was used to detect CRBN-DDB1/BRD4 dimerization induced by dBET molecules. In brief, GST-BRD4[49-170] (Sigma Aldrich) and CRBN-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM65456(pomalidomide | US9694015, 6.2 | 19171-19-8 | 4-ami...)
Affinity DataIC50: 63.1nMAssay Description:A thalidomide competition AlphaScreen assay was employed to measure the binding affinity (IC50) of thalidomide conjugates and novel IMiDs to CRBN-DDB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM511650(US11059801, Compound D-16)
Affinity DataIC50: 71.4nMAssay Description:A thalidomide competition AlphaScreen assay was employed to measure the binding affinity (IC50) of thalidomide conjugates and novel IMiDs to CRBN-DDB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

LigandPNGBDBM511628(US11059801, Compound dBET36)
Affinity DataIC50: 80.3nMAssay Description:AlphaScreen technology was used to detect CRBN-DDB1/BRD4 dimerization induced by dBET molecules. In brief, GST-BRD4[49-170] (Sigma Aldrich) and CRBN-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

LigandPNGBDBM511602(US11059801, Compound dBET10)
Affinity DataIC50: 83nMAssay Description:AlphaScreen technology was used to detect CRBN-DDB1/BRD4 dimerization induced by dBET molecules. In brief, GST-BRD4[49-170] (Sigma Aldrich) and CRBN-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2022
Entry Details
US Patent

Displayed 1 to 50 (of 108 total ) | Next | Last >>
Jump to: